| Autor: |
Melnichnikova OS; V.A. Almazov National Medical Research Center, St.Petersburg, Russia., Nazarova IA; V.A. Almazov National Medical Research Center, St.Petersburg, Russia., Sirotkina OV; V.A. Almazov National Medical Research Center, St.Petersburg, Russia; Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre 'Kurchatov Institute', St.Petersburg, Russia., Panov AV; V.A. Almazov National Medical Research Center, St.Petersburg, Russia., Abesadze IT; V.A. Almazov National Medical Research Center, St.Petersburg, Russia., Alugishvili MZ; V.A. Almazov National Medical Research Center, St.Petersburg, Russia., Lokhovinina NL; V.A. Almazov National Medical Research Center, St.Petersburg, Russia., Vavilova TV; V.A. Almazov National Medical Research Center, St.Petersburg, Russia. |
| Abstrakt: |
Despite the fact that acetylsalicylic acid (ASA) is the "gold" standard for the prevention of cardiovascular complications in patients with coronary heart disease (CAD), a number of patients still have risks of atherothrombosis. In the present study, the antithrombotic effect of ASA in patients with CAD was assessed in platelet-rich plasma (PRP) using integral tests of the hemostasis study: the T-TAS system (Total Thrombus-formation Analysis System) and the thrombin generation test (TGT). The study involved 34 patients with stable CAD (11 women, 23 men) and people (15 women, 18 men) in the control group. As a result of assessing the activity of thrombus formation using the T-TAS system, a significant decrease in the area under the curve (AUC10) was found in the group with CAD patients compared with the control (135.6 [88.0-222.3] and 260.5 [217.3-301.9], respectively, p. |
